Discussion about this post

User's avatar
Alex Washburne, PhD's avatar

This reminds me of a problem I worked on while at Sandia National Labs: how to better inform nuclear reactor operators in a Fukushima-like disaster.

The Earthquake forced the reactor into a SCRAM procedure, shoving control rods into the mix to capture neutrons and slow the fission reaction, but the tsunami shut off the backup diesel power behind the pump. With the lights off and pump no longer providing cool water, the operators ran around with a physical battery like an EKG trying to restart circulation. What they missed, however, was information that might’ve informed when to abandon this pursuit. From simulations of nuclear meltdowns, we found key sensors within the reactor pressure vessel were essential to identifying the buildup of hydrogen gas (from super hot water interacting with the zirconium cladding on the control rods), and had the operators noticed these signals in the deluge of sensor data in the reactor, they could’ve dropped the battery and ran away before boom.

The task informs the data, and heterogeneity (in space, time, across cells) relevant for one task may be irrelevant for another. Another example is the method my mom and I used to improve the efficacy of chemo for her pancreatic cancer: heterogeneity in the phase of the cell cycle across cancer cells affects the efficacy of chemotherapies like nucleoside analogs that inhibit DNA synthesis during the S phase of the cell cycle. Where we can exert forcing on the system, such as with fluctuations in blood glucose that modulate the rate of cell cycle progression, we may be able to learn from and exploit the heterogeneity in cell cycle phase, maximizing the number of cells in the S phase of the cell cycle at the time of infusions. Here, the task was curing my mom, and the relevant data ended up being a few peepholes of ancillary, often supplementary, graphs in papers that suggested variation in glucose concentrations can lead to significant variation in the rate at which cells progress out of G1 and into S phase. While using a customized glucose-forcing regime in conjunction with nucleoside analog infusions, my mom showed one of the most extreme responses to chemotherapy, her stage IV tumor disappearing by her 17mo post-diagnosis scans.

With loops in automated labs, there’s often the foundation model task - just explore the space widely, capturing significant variation to improve model robustness. However, the economics may be better in the diagnostics or therapeutics tasks, in which case the economic value of a loop depends on the reliability of biomarkers as assays of efficacy and safety (let alone absorption, diffusion, metabolism, excretion, toxicity in vivo).

Loved reading your thoughts! My new favorite phrase: “heroic assumptions” 😂🫡

Paul O'Sullivan's avatar

I read this slowly because it feels like a big part of the methodology required to reach Ray Kurzweil’s idea of running clinical trials in an hour on a super computer. For that understanding biology with enough fidelity to model what a medicine will actually do is the foundation.

From a manufacturing perspective, I would add that we do not have enough data. We need much more, captured with its context at the edge. Cleaning disconnected signals later in the cloud is inefficient and cannot recover context that was never preserved. Which is the problem today you are hitting on. In a biological process, the signal we discard today may explain tomorrow’s failure.

I would love to see bioreactors designed around the approach you describe where sensors are placed very deliberately, instruments calibrated, clocks synchronized, and every signal mapped to the state or transition under study. At the point of collection, we should know the instrument was within tolerance, the process context was intact, and the sample was correctly timed against relevant events.

Trust should be built into the data, not inferred afterward.

We have traditionally done a poor job of this in both cGMP manufacturing and research. It can be very different now. The edge is the right place for this work to happen. A bioreactor should make product and leave a defensible record of what happened to the biology, when it happened, and under what conditions.

Great article.

1 more comment...

No posts

Ready for more?